Tags : Ascendis Pharma

Ascendis Pharma Reports Results of TransCon Growth Hormone in P-III

Shots: The P-III HEIGHT study involves assessing of Transcon Growth Hormone (hGH) n=105 vs Pfizer’s Genotropin (n=56) in 161 children with GHD in ratio 2:1 The P-III HEIGHT study resulting in meeting its 1EPs, non-inferior/superior to Pfizer’s Genotropin, annualized height velocity (AHV) @52 wks. (11.2 cm/yr. vs 10.3 cm/yr.), AEs (1% vs 1.8%), safe & tolerable […]Read More